EPHA2 and cancer: EphA2 has been long recognized as a potential therapeutic target, being overexpressed in a range of cancer types, including both mesenchymal tumors such as melanoma and glioma, and epithelial tumors including prostate, breast, ovarian, lung, colon, esophageal, gastric, cervical, and bladder cancers [12].